TNF and breast cancer: Thus, ATR-II abated proinflammatory cytokines (TNF-α and IL-6), reduced oxidative markers (MDA and 8-OH-dG) and increased GSH/GSSG ratio in the mammary glands, which suggested that ATR-II had anti-inflammatory and antioxidant activities in the NMU-induced rat breast cancer model.